• No results found

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight‐Control Clinical Trial and an Observational Cohort

N/A
N/A
Info
Download
Protected

Academic year: 2019

Share "Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight‐Control Clinical Trial and an Observational Cohort"

Copied!
26
0
0

Loading.... (view fulltext now)

Download now ( 26 Page )

Full text

Loading

Figure

Table 1: Responsiveness of individual items and indices, ranked by t value in the TICOPA trial
Table 2: Discriminative capacity of disease activity state definitions in the TICOPA trial
Table 3 - LOPAS II Sensitivity to change of the RAPID3 with other disease outcomes

References

Download now ( PDF - 26 Page - 286.41 KB )

Related documents

Patient education, disease activity and physical function: Can we be more targeted? A cross sectional study among people with rheumatoid arthritis, psoriatic arthritis and hand osteoarthritis

CDAI: Clinical disease activity index; DAPSA: Disease activity index for psoriatic arthritis; DAS 28: Disease activity score 28; ENAT: Educational needs assessment tool; HAQ:

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. The

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial

(12 more authors) (2016) Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical

Improved patient reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Adjusted mean changes from baseline to weeks 16 (all patients) and 24 (non-EE responders) in Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form-36 (SF-36;

A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial

RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

ACR, American College of Rheumatology; ADA, adalimumab; DAPSA, Disease Activity in Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; HAQ-DI, Health

Rheumatoid Arthritis and Treat-to-Target

RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to